Vimarsana
Biggest News Aggregation in the World

Paulv Goode News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Paulv Goode. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Paulv Goode Today - Breaking & Trending Today

GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT - Vimarsana News

GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Rutherford, NJ, April 22, 2024 -- Glucotrack, Inc. , a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today...

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS - Vimarsana News

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

Rutherford, NJ, Feb. 13, 2024 -- Glucotrack, Inc. , a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes announced...

GlucoTrack transitions strategic focus to implantable CGM - Vimarsana News

GlucoTrack transitions strategic focus to implantable CGM

Glucotrack (Nasdaq:GCTK) President and CEO Paul V. Goode today issued a statement to shareholders outlining strategic changes.

Related Topics:
Paulv Goode
Integrity Applications, Inc.: Integrity Applications Issues Shareholder Update Letter - Vimarsana News

Integrity Applications, Inc.: Integrity Applications Issues Shareholder Update Letter

Wilmington, DE and Or Yehuda, Israel, Dec. 20, 2021), a non-invasive device for measuring glucose levels in people with Type II diabetes and prediabetes announced today that Paul V. Goode, PhD, President

Integrity Applications, Inc.: Integrity Applications Announces Uplisting to Nasdaq Capital Market - Vimarsana News

Integrity Applications, Inc.: Integrity Applications Announces Uplisting to Nasdaq Capital Market

Wilmington, DE and Or Yehuda, Israel, Dec. 08, 2021), a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that its shares of common stock